<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04230408</url>
  </required_header>
  <id_info>
    <org_study_id>LACOG 2218</org_study_id>
    <nct_id>NCT04230408</nct_id>
  </id_info>
  <brief_title>Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers</brief_title>
  <acronym>PACIFIC BRAZIL</acronym>
  <official_title>Intensified Chemo-immuno-radiotherapy With Durvalumab (MEDI4736) for Stage III Non-Small Cell Lung Cancers (NSCLCs): a Brazilian Single Arm Phase II Study (PACIFIC BRAZIL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Latin American Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Latin American Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study that will assess if Durvalumab (MEDI4736) used as induction&#xD;
      chemo-immunotherapy followed by concurrent chemo-immuno-radiotherapy and consolidation&#xD;
      immunotherapy may improve oncologic outcomes compared with standard of care chemoradiation&#xD;
      followed by durvalumab (as in the PACIFIC trial) with a reasonable safety profile.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, non-randomized, open label, single arm, multi-institutional, phase 2 study,&#xD;
      including patients with stage III non-small cell lung cancer able to receive concurrent&#xD;
      chemoradiation. Eligible patients will then receive treatment as follows:&#xD;
&#xD;
      Induction chemo-immunotherapy Two 21-day cycles of carboplatin, paclitaxel and durvalumab&#xD;
      will be given BEFORE concurrent chemo-immuno-radiotherapy.&#xD;
&#xD;
      Thereafter, patients without progressive disease (or patients with disease progression that&#xD;
      is still locally advanced and can be safely encompassed within tolerable radiation fields)&#xD;
      will receive concurrent chemo-immuno-radiotherapy, as follows:&#xD;
&#xD;
      Concurrent chemo-immuno-radiotherapy Concurrent carboplatin, paclitaxel, and durvalumab with&#xD;
      radiation therapy, initiated preferably 3-5 weeks after the last dose of induction&#xD;
      chemo-immunotherapy.&#xD;
&#xD;
      Thereafter, patients without progressive disease will receive consolidation immunotherapy, as&#xD;
      follows:&#xD;
&#xD;
      Consolidation immunotherapy Twelve 28-day cycles of durvalumab will be given, initiated&#xD;
      preferably within one week following concurrent chemo-immuno-radiotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective single-arm study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12 months Progression-Free Survival</measure>
    <time_frame>Tumor scans will be performed at baseline, after the induction and concomitant phases and 3, 6, 9, and 12 months after the last dose of radiation therapy.</time_frame>
    <description>Proportion of patients who are alive and progression-free 12 months after cycle 1, day 1 of induction treatment, estimated by the Kaplan-Maier method and using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>OS will be evaluated until month 24 after C1D1.</time_frame>
    <description>Time from cycle 1, day 1 of induction treatment until death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate to induction treatment</measure>
    <time_frame>Tumor scans will be performed at baseline, after the induction and concomitant phases and 3, 6, 9, and 12 months after the last dose of radiation therapy.</time_frame>
    <description>The proportion of patients with at least one tumor scan of complete response (CR) or partial response (PR) using RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of Failure</measure>
    <time_frame>Tumor scans will be performed at baseline, after the induction and concomitant phases and 3, 6, 9, and 12 months after the last dose of radiation therapy.</time_frame>
    <description>Rate of disease failure in local, regional and distant sites</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>DURVALUMAB (MEDI4736) + carboplatin-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chemo-immunotherapy phase:&#xD;
Two cycles of Paclitaxel 200 mg/m2, Carboplatin AUC 6 and Durvalumab 1500 mg intravenously every 21 days.&#xD;
Concurrent chemo-immuno-radiotherapy phase:&#xD;
Radiation therapy concomitantly with: paclitaxel 50 mg/m2 intravenously every 7 days (+/- 3 days) until completion of radiation therapy, carboplatin AUC 2 intravenously every 7 days (+/- 3 days) until completion of radiation therapy and durvalumab 1500 mg intravenously every 21 days (+/- 6 days) for a maximum of 2 doses.&#xD;
Concurrent chemo-immuno-radiotherapy:&#xD;
Durvalumab 1500 mg intravenously every 28 days (+/- 7 days) for a maximum of 12 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Intensified chemo-immuno-radiotherapy with durvalumab in combination with carboplatin, paclitaxel and radiation</description>
    <arm_group_label>DURVALUMAB (MEDI4736) + carboplatin-paclitaxel</arm_group_label>
    <other_name>Carboplatin</other_name>
    <other_name>Paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          1. Histologically or cytologically confirmed non-small cell lung cancer.&#xD;
&#xD;
          2. Stage III according to the American Joint Committee on Cancer (AJCC) Staging Manual,&#xD;
             8th edition.&#xD;
&#xD;
          3. No prior systemic therapy, radiation therapy, or surgery for the current cancer.&#xD;
&#xD;
          4. Age ≥ 18 years at time of study entry&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          6. Body weight &gt;30kg&#xD;
&#xD;
          7. Pre- or post-bronchodilator forced expiratory volume 1 ≥ 1.2 litres/second or ≥ 50% of&#xD;
             predicted value&#xD;
&#xD;
          8. Adequate normal organ and marrow function&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          1. Patients whose radiation treatment is likely to encompass a volume of whole lung&#xD;
             receiving ≥ 20 Gy in total of more than 35% of lung volume.&#xD;
&#xD;
          2. Patients whose radiation treatment is likely to deliver a cardiac dose V50 &gt; 25%&#xD;
&#xD;
          3. Known allergy or hypersensitivity to any of the study drugs or any of the study drug&#xD;
             excipients&#xD;
&#xD;
          4. Participation in another clinical study with an investigational product with&#xD;
             anti-neoplastic activity during the last 3 weeks prior to treatment initiation&#xD;
&#xD;
          5. Concurrent enrolment in another clinical study, unless it is an observational&#xD;
             (non-interventional) clinical study or during the follow-up period of an&#xD;
             interventional study&#xD;
&#xD;
          6. History of allogenic organ transplantation.&#xD;
&#xD;
          7. Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the&#xD;
             exception of alopecia, vitiligo, and the laboratory values defined in the inclusion&#xD;
             criteria&#xD;
&#xD;
          8. Current or prior use of immunosuppressive medication within 14 days before the first&#xD;
             dose of durvalumab.&#xD;
&#xD;
          9. Prior randomisation or treatment in a previous durvalumab clinical study regardless of&#xD;
             treatment arm assignment.&#xD;
&#xD;
         10. Patients who have received prior anti-PD-1, anti PD-L1 or anti CTLA-4 antibodies&#xD;
&#xD;
         11. Receipt of live attenuated vaccine within 30 days prior to the first dose of&#xD;
             investigational product.&#xD;
&#xD;
         12. Prior radiation therapy to the region of the study cancer that would result in overlap&#xD;
             of radiation therapy fields.&#xD;
&#xD;
         13. Major surgical procedure (as defined by the Investigator) within 28 days prior to the&#xD;
             first dose of the investigational product.&#xD;
&#xD;
         14. Active or prior documented autoimmune or inflammatory disorders&#xD;
&#xD;
         15. Uncontrolled intercurrent illness&#xD;
&#xD;
         16. History of another primary malignancy&#xD;
&#xD;
         17. Known active infection including tuberculosis , hepatitis B, hepatitis C, or human&#xD;
             immunodeficiency virus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gustavo Werutsky</last_name>
    <phone>+55 51 3384 5334</phone>
    <email>gustavo.werutsky@lacogcancerresearch.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Voelcker</last_name>
    <phone>+55 51 3384 5334</phone>
    <email>laura.voelcker@lacogcancerresearch.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Liga Norte Riograndense Contra o Câncer</name>
      <address>
        <city>Natal</city>
        <state>Rio Grande Do Norte</state>
        <zip>59075-740</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Danielli Matias, MD</last_name>
      <phone>55 84 4009 5595</phone>
      <email>danielli.matias@liga.org.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CPO</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gustavo Werutsky</last_name>
    </contact>
    <investigator>
      <last_name>Gustavo Werutsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INCA</name>
      <address>
        <city>Rio De Janeiro</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luiz Henrique de Lima Araújo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>COI Américas</name>
      <address>
        <city>Rio De Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luiz Henrique de Lima Araujo</last_name>
    </contact>
    <investigator>
      <last_name>Luiz Henrique de Lima Araujo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beneficiencia Portuguesa de São Paulo/Hospital São José</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William William</last_name>
    </contact>
    <investigator>
      <last_name>William William, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICESP</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilberto Castro, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gilberto Castro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 10, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stage III Non-Small Cell Lung Cancer</keyword>
  <keyword>Unresectable Non-Small Cell Lung Cancer</keyword>
  <keyword>Durvalumab</keyword>
  <keyword>MEDI4736</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

